Business, Drugs and Pharmaceuticals, Free News Articles, Reports and Studies

iCell Gene Therapeutics Announces cCAR-T Clinical Publication in the Stem Cell Reviews and Reports Journal

STONY BROOK, N.Y. -- iCell Gene Therapeutics, a clinical stage biopharmaceutical company focused on immunotherapies for hematologic malignancies, solid tumors, organ rejections and autoimmune disorders, today announced the publication of their clinical study utilizing cCAR T-cell immunotherapy to successfully treat a patient with lupus. Their CAR is directed against CD19 and BCMA surface proteins generating a cCAR with dual expression of CD19 and BCMA CAR molecules. Their cCAR is one of a kind in the family of engineered CAR T-cells researchers are studying.

Their report "Treatment of Systemic Lupus Erythematosus Using BCMA-CD19 Compound CAR" published on August 30, 2021, shows the clinical success of cCAR in treating a patient with Systemic Lupus Erythematosus (SLE).

According to Dr. Yupo Ma, founder of iCell Gene Therapeutics, "After a single infusion of CD19-BCMA cCAR the patient achieved undetectable levels of autoantibodies that mediate SLE, successfully treating the patient's SLE for 2 years without the need for additional medications."

The publication is available online at https://doi.org/10.1007/s12015-021-10251-6.

About SLE

Systemic lupus erythematosus (SLE) is an antibody-mediated autoimmune disease, in which autoantibodies attack its own tissues, resulting in widespread tissue damage in the affected organs including kidneys, lungs, joints, brain and blood vessels. According to the Lupus Foundation of America, it estimates that 1.5 million Americans, and at least five million people worldwide, have a form of lupus.

About CD19-BCMA cCAR Therapy

iCell has developed a novel compound Chimeric Antigen Receptor (cCAR)approach. In this approach, the cCAR T cells express two distinct and fully functional CAR molecules, one that targets the molecule CD19 present on B cells and one that targets BCMA, which is present on plasma cells. In their recently published paper, researchers have shown that this cCAR led to rapid and dramatic decreases in B cell levels and levels of "autoantibodies" (antibodies that attack the body's own cells) in a patient with SLE.

As B cells are part of the normal immune system, it is preferable that the elimination of B cells be temporary. After 9 months of B cell depletion, the patient's B cells returned to normal. Importantly, the levels of autoantibodies remained undetectable. Based on these results, the researchers concluded that cCAR effectively "reset" the antibody-producing populations. In this "reset," the problematic cell populations were removed, leaving behind a fresh, clean slate. From this, new B cells and plasma cells were eventually formed, which did not have the same autoantibody-producing properties. Because of this, the patient has not had further lupus symptoms despite receiving no additional medications for over 2 years.

Given the prevalence of antibody-mediated disorders, this cCAR may prove useful for a variety of different medical conditions.

Sjögren's Syndrome, autoimmune hemolytic anemia, neuromyelitis optica spectrum disorder, celiac disease, type 1 diabetes, inflammatory bowel disease, rheumatoid arthritis, psoriasis, and multiple sclerosis all incorporate autoantibody formation in disease pathogenesis. Additionally, organ rejection following transplantation may be mediated by antibodies. By "resetting" the immune system prior to organ transplantation, this antibody-mediated rejection may be avoided. More research is needed on the long-term efficacy and safety of this treatment, but future applications of cCAR has a large window of opportunity.

About iCell Gene Therapeutics

iCell Gene Therapeutics, located in Stony Brook, New York, is a clinical-stage biopharmaceutical company developing first-in-class chimeric antigen receptor engineered cells. Their main focuses are on autoimmune disorders, AML, and T-cell malignancies. Their current clinical trials utilize their CARvac, T-cell targeted CARs, cCARs and non-gene edited universal CARs engineered as treatments for cancer, organ rejections and autoimmune diseases. These studies are ongoing in the US and China for their use.

For more information, please visit http://icellgene.com/

CONTACT:
Media and Investors
Kevin Pinz
Tel: (631) 538-6218
Kevin.pinz@icellgene.com

RELATED LINKS:

https://www.lupus.org/resources/how-many-people-have-lupus-in-the-united-states

https://www.lupus.org/resources/what-is-lupus

Related link: http://icellgene.com/

This news story was published by the Neotrope® News Network - all rights reserved.

Awards and Honors, Business, Free News Articles

Ruby Slipper Swivel Car Seat Cover Wins New Product Award

ST. CLAIRSVILLE, Ohio -- The inventor of the Ruby Slipper Swivel Car Seat Cover, Katherine Miles, is excited to announce that this deceptively simple mobility product has earned the New Product Pavilion Providers' Choice Bronze Award at the 2021 Medtrade West national trade show. Sponsored by HomeCare Magazine, the honor highlights the potential of the Ruby Slipper to make a difference in the lives of seniors and others with limited mobility.

The Ruby Slipper Swivel Car Seat Cover helps people enter and exit a vehicle seat with ease, allowing seniors with limited mobility and persons recovering from injury or surgery to get to the places they want and need to go: visiting friends and family, running errands and going to medical appointments.

"To be selected for this award by our fellow Medtrade attendees means a lot," said Miles. "It's real confirmation that our simple little product can be a life-changer for many people. We are so grateful to Medtrade West and HomeCare Magazine for the opportunity to spread the word about the Ruby Slipper!"

"We're probably one of the lowest-tech products here," said Steve Porcaro, Ruby Slipper's Director of Business Development. "You don't have to change the battery, you don't have to learn to operate it. Just put it on the seat, set it up and you're good to go. People were very excited about the simplicity and the ease, and how comfortable and simple it was. And everyone said the same thing: how come I didn't think of that?"

Miles and the Ruby Slipper team look forward to making more connections at the upcoming Medtrade East event in October 2021 in Atlanta.

About Medtrade West and HomeCare Magazine

Held July 12-14 in Phoenix, Medtrade West marked Ruby Slipper's return to its first in-person national trade show in eighteen months. The nation's largest home medical equipment exhibition and conference, Medtrade has been helping the industry grow since 1979.

HomeCare is the leading business magazine for home medical equipment and home health professionals.

About the Ruby Slipper Swivel Car Seat Cover

The Ruby Slipper Swivel Car Seat Cover is a specially designed, heavy-duty double-layered seat cover with a unique sliding action that allows passengers to swivel in and out of the car seat with ease. This simple seat cover allows passengers to quickly and easily enter or exit virtually any vehicle. The Ruby Slipper is comfortable, convenient and helps reduce stress while traveling. It is intended for anyone with limited mobility and strength, or recuperating from a recent surgery.

The Ruby Slipper fits virtually all passenger cars and trucks, is easily installed in minutes, works on both cloth and leather seats, and can be moved from car to car as needed. The nylon fabric is rugged, comfortable and easy to care for.

About Ruby Slipper, LLC

Made entirely in America, the Ruby Slipper Swivel Car Seat Cover can be purchased online at https://www.rubyslipperswivelcarseatcover.com/ (via PayPal) or by calling 877-855-3065. The cost is $79.95 plus $11.95 shipping. The Ruby Slipper comes with a 30-day money back guarantee.

Questions can be directed to https://www.rubyslipperswivelcarseatcover.com/contact or 877-855-3065. Ruby Slipper, LLC is located at P.O. Box 508, St. Clairsville, Ohio, 43950.

MULTIMEDIA:

VIDEO (YouTube): https://youtu.be/334V1cefQtA

Related link: https://www.rubyslippercarseatcover.com/

This news story was published by the Neotrope® News Network - all rights reserved.

Business, Free News Articles

Spodak Dental Group’s Use of ‘Laughing Gas’ Helps Patients Who Suffer from Depression

DELRAY BEACH, Fla. -- The Spodak Dental Group team is committed to helping their patients not only achieve their smile goals, but also their overall comfort in and out of the dental chair. While nitrous oxide has been offered as an effective treatment for anxious or fearful patients, it has now been shown to help with patients who suffer from depression.

A recent study published in Science Translational Medicine has shown that nitrous oxide, or laughing gas, can relieve symptoms of depression otherwise resistant to current drugs. The randomized phase II clinical trial of 24 volunteers in the United States with treatment-resistant major depression shows that a low dose of nitrous oxide offers a benefit that appears to last for several weeks and come with very few side effects.

The first treatment involved an hour-long high dose of nitrous oxide (at 50 percent), the second involved an hour-long low dose of the drug (at 25 percent), and the last involved a placebo. The majority of people in the trial showed a high rate of response and symptom improvement over the course of the trial. This is the first time that a study has shown these results.

The Spodak Dental Group state-of-the-art facility offers nitrous oxide in each of the 18 state-of-the-art operatories. Patients are invited to enjoy nitrous oxide for any treatment or procedure, including cleanings, which are monitored by board certified general and specialty dentists.

"We are committed to our patients' overall safety, health and wellness, which is why we safely offer nitrous oxide," said Dr. Craig Spodak, general dentist at Spodak Dental Group. "Not only is it a safe option for anxious or depressed patients, the effects dissipate quickly once the gas is not inhaled and there are no negative side effects."

The Spodak Dental Group, a 2017 Inc. 5000 honoree, has evolved to become South Florida's premier, comprehensive dental facility, and comprises a world-class association of dental professionals poised to provide full-service dental care second-to-none in both scope and skill. The Spodak Dental Group team includes General and Restorative Dentists, Endodontists, Periodontists, Board Certified Oral and Maxillofacial Surgeons, Master Ceramic Artists and Anesthesiologists, as well as one of the nation's only in-office dental labs.

Spodak Dental Group is located at 3911 W. Atlantic Ave. Call or text (561) 303-2413 or visit https://www.SpodakDental.com for more information or to schedule a virtual or in-office appointment.

Related link: https://www.spodakdental.com/

This news story was published by the Neotrope® News Network - all rights reserved.

Alliances and Partnerships, Business, Free News Articles

youturn and First Sun Partner to Provide EAP clients with Innovative Substance Misuse Support

GREENVILLE, S.C. -- youturn, the world's largest platform of evidence-based and therapist led video content for Stress, Anxiety, and Substance Misuse, announced a partnership with First Sun EAP. Through the partnership, youturn and First Sun will co-market services to help enterprises decrease employee stress and anxiety while increasing resilience and productivity.

The partnership will provide First Sun clients with access to youturn's risk mitigation training content for businesses and the youturn library will supplement First Sun's expansive employee and leader support programs.

youturn's CEO, Shay Houser, said, "First Sun is the leading EAP in the Southeast. Serving over 150,000 lives, we believe our combined efforts can reduce employee Stress, Anxiety, and Depression (SAD) while minimizing the impact of substance misuse inside the enterprise."

According to Maria Lund, First Sun's president and COO, "Our business is designed to grow with the needs of our customers. Offering youturn is a great added-value service that aligns with the how we are helping our customers support their employees through this difficult time."

A New Solution to a Growing Epidemic:

First Sun EAP has witnessed the transformation of mental and emotional assistance for employees for decades and, since the onset of the pandemic, has seen first-hand the impact of the rise in mental illness and decline in well-being. There is clear evidence for the need and value of organizations investing in substantial support for employees around stress, anxiety and depression. Additionally, the national rise in substance misuse is impacting every business.

According to a Gallop Poll, close to half of U.S. adults, 46%, have dealt with substance use problems in their family. And that was pre-COVID-19. Substance Misuse amongst employees has accelerated to epidemic levels. And, the missing link in the well-being of employees, is the impact of loved ones at home who are struggling. This trend is a silent killer of productivity, and more importantly, people.

First Sun and youturn intend to address this crisis by combining youturn's evidence-based educational content with First Sun's extensive clinical and workplace expertise.

"An increasing number of employees struggling with mental health challenges are reaching out to First Sun for help," said Maria Lund. "It is our goal to make our broad array of services accessible to everyone. We can now expand our convenient well-being solutions to include youturn's powerful suite of offerings."

About youturn

youturn maintains the world's largest library of proprietary, therapist-led, video content about substance misuse. youturn's team has lived experience and have supported tens of thousands of individuals and families navigate the world of substance misuse. youturn has been utilized by leading institutions such as the Illinois Army Reserves, University of South Carolina Medical School, Clemson University School of Medicine, The South Carolina Veterans Administration, Prisma Health as, and numerous publicly held enterprises. Learn more: https://youturn.net/.

About First Sun

First Sun EAP is a leading provider of well-being solutions for work, home and life. We collaborate with enterprises and groups so their entire population is covered through our comprehensive well-being services: full service EAP, population programs, training and development, and critical incident response. Our integrated approach to well-being reduces the overwhelming challenges people face every day and supports leaders with tools to create success. For more information or to get a quote visit https://firstsuneap.com/.

MEDIA CONTACTS:

youturn: Shay Houser, CEO, 864.373.5007

First Sun: Maria Lund, President/COO, maria.lund@firstsuneap.com 803-530-2748

Related link: https://youturn.net/

This news story was published by the Neotrope® News Network - all rights reserved.

Alliances and Partnerships, Business, Education and Schools, Free News Articles

Final TeethXpress guided full-arch, immediate-load dental implant course of 2021 to be held in Las Vegas

BIRMINGHAM, Ala. -- TeethXpress will hold its final full-arch, immediate-load course taught from a guided treatment perspective Sept. 25-26, 2021, in Las Vegas, Nevada. Led by noted periodontist Curry H. Leavitt, DMD, MS, of Red Rock Periodontics & Implantology, the course will take place over two days at the Red Rock Institute implant training center in Las Vegas. Attendees will participate in hands-on training and view a live surgery, all while earning 16 CE credits.

Dr. Leavitt will present new materials and cover the new nSequence guide design.

"It's been such a touch-and-go year with COVID-19, but the feedback from doctors who attended our hands-on guided course in January was so positive, we had to make room for another date this year," said Dr. Leavitt. "Since then, I've added new material that covers several immediate, fixed-hybrid implant cases, including the new nSequence guide design. I can hardly wait to share these experiences with colleagues."

Remaining space is limited. Register today to reserve your seat.

Not only will doctors receive an opportunity to participate in a comprehensive hands-on, didactic guided surgery training session, they'll also have an opportunity to watch Dr. Leavitt perform a live surgery and immediate, fixed-hybrid prosthetic conversion using a CT-based, stackable guide. The live surgery will involve a partially edentulous maxillary arch. Four to six dental implants and multi-unit abutments will be placed using the BioHorizons Tapered Pro system.

January 2021 course attendees were outwardly complementary of pearls they picked up on the proper digital treatment planning.

"Dr. Leavitt's lecture and presentation were truly phenomenal," said Dr. Wladimir Gedeon, OMS. "The way he masters digital workflow is brilliant."

As one of the nation's most experienced implant laboratory technicians, Jeff Carlson, CDT, Senior nSequence Implant Specialist, will be present to support this digital learning experience.

"Supporting Dr. Leavitt and the TeethXpress team in training doctors on this advanced, guided, implant protocol is quite humbling," said Carlson. "Dr. Leavitt is so down to earth and has a way of engaging doctors that makes this course an exceptional learning experience. Before you know it, doctors are not only learning from his lectures, but they're picking up invaluable insights from each other."

Proceed(r) Finance will present their treatment financing resources patients can use to make dental implants more affordable. There aren't many financial institutions in this space who can offer up to $70,000 in unsecured treatment financing to patients in need of large dollar dental procedures, such as "all-on-4" dental implant therapy.

"Anyone attending this September TeethXpress course should expect to be in for a great learning experience," said Dr. Leavitt. "I'm excited just thinking about it!"

There may be no better time to visit Las Vegas than in the fall, according to U.S. News & World Report. Travel expenses are lower than the summer and winter months and high temperatures begin to drop into the low 70s.

Register today at: https://web.cvent.com/event/7c81dc2f-7ef0-4dac-853b-11fe2af4ea53/register

About TeethXpress Courses

TeethXpress(r) is a registered trademark of BioHorizons. TeethXpress dental implant courses are focused on training dentists on full-arch, immediate, fixed-hybrid implant procedures, or All-on-X. Implant surgeons and restorative dentists can train to perform All-on-X procedures using either a conventional or fully guided digital approach through these two-day CE courses. TeethXpress courses are currently held in major U.S. cities, including San Diego, California; Providence, Rhode Island; Cleveland, Ohio; Las Vegas, Nevada; and New City, New York. More than 1,400 dentists have been trained at a TeethXpress course.

Headquartered in Birmingham, Alabama, BioHorizons is the third-largest dental implant company in the world. BioHorizons helps customers restore smiles in more than 90 countries throughout North America, Europe, South America, Asia, Africa and Australia.

Learn more at: https://www.teethxpress.com/

Twitter: @biohorizons

MEDIA CONTACT
Jaclyn Walz
Senior Practice Development Associate
TeethXpress
info@teethxpress.com
205-986-1237

MULTIMEDIA:

*PHOTO link for media: https://www.Send2Press.com/300dpi/21-0831s2p-dr-leavitt-300dpi.jpg

*Caption: Dr. Curry Leavitt, periodontist, TeethXpress guided implant course instructor.

Related link: https://www.teethxpress.com/

This news story was published by the Neotrope® News Network - all rights reserved.

Business, Electronics, Free News Articles, Product Launches

Olea Kiosks, Inc. Delivers Height Adjustable Austin Kiosk for Healthcare

LOS ANGELES, Calif. -- Olea Kiosks®, Inc., a visionary provider of innovative self-service kiosk solutions, today announced the addition of its height adjustable base for the Austin series kiosk. This new addition is available for ordering now.

Aimed at healthcare, this unit delivers full ADA (Americans with Disabilities Act) height compliance as all of the user touch points can be positioned at a height under 48 inches. At the push of a button, the base raises and lowers a total of 11.9 inches to provide users of all heights and abilities an improved user-experience.

The Austin is the most popular kiosk Olea sells with over 2500 sold since its inception in 2018 The Austin Height Adjustable (HA) combines the height adjustable base with the desktop unit to deliver a slick, compact and versatile self-service solution perfect for healthcare check-in. The Austin is also very popular with hospitality and frequently used in quick-serve restaurants (QSR) and ticketing where this functionality is a welcome addition.

"The Austin HA comes at a time when healthcare and businesses in general are constrained by the lack of human resources available," said CEO Frank Olea. "Our engineering team worked extra hard to turn this unit around in a record amount of time," added Olea.

In addition, an optional UV sanitizing system utilizing two powerful Mercury Vapor bulbs are now available with all of the Austin model kiosks. The cleaning cycle allows for sanitization of the touchscreen as well as the payment device. "We're excited to bring this feature to market as we felt there was a need to keep not only the screens clean but the buttons on the pin-pads as well," added Olea.

The Austin series kiosk is now available in 4 options: the HA, the Freestanding (FS), the Desktop (DT), and the Wall-mount (WM). The Austin model supports a host of external devices.

Link to video: https://vimeo.com/591165564/21b4f37bdd

About Olea Kiosks®, Inc.

Olea Kiosks Inc., is a self-service kiosk solution provider for the attractions and entertainment, healthcare and hospitality industries. Its technologically advanced, in-house manufacturing, design, and innovation have made it an industry leader. Headquartered in Los Angeles, California, customers include Cedars-Sinai, Kaiser Permanente, Tenet, The Habit Burger Grill, The Empire State Building, Universal Studios, Scientific Games, and Subway.

For more information, visit https://www.olea.com/.

MULTIMEDIA:

*PHOTO link for media: https://www.Send2Press.com/300dpi/21-0824s2p-olea-austin-300dpi.jpg

*Caption: The Austin Height Adjustable Kiosk.

Related link: https://www.olea.com/

This news story was published by the Neotrope® News Network - all rights reserved.

Business, Free News Articles

Vyriad, Inc. Appoints Harry Hoffman to its Board of Directors

ROCHESTER, Minn. -- Vyriad, Inc., a clinical-stage biotechnology company developing oncolytic virus therapies to treat a wide range of cancers, today announced the appointment of leading life sciences investor Harry Hoffman to the Company's board of directors.

During Harry's 25 years of service as Mayo's Chief Investment Officer and Treasurer which ended December 2020, Mayo Clinic achieved top decile investment performance among a universe of major tax-exempt institutions and grew its investment assets by over ten-fold. Outside of Mayo, Harry has served on the boards of several large family offices and is a former trustee of the Endowment Board of the American Red Cross, The Investment Fund for Foundations (TIFF) and The Ronald McDonald House of Rochester. He is also a founding member and vice chair of the Southeast Minnesota Capital Fund.

"I am delighted to welcome Harry onto the Vyriad Board. He has a deep understanding of Vyriad and its history, and I am very much looking forward to working with him as we take this exciting Company to its next level," said Ed Kania, Vyriad's Chairman of the Board.

About Vyriad, Inc.

Vyriad is a clinical-stage company developing virus-based therapeutics, focusing initially on proprietary oncolytic virus therapies for the treatment of cancers with significant unmet needs. Founded by scientists at Mayo Clinic and the University of Miami, Vyriad programs viruses to selectively attack cancer cells, thereby igniting antitumor immune responses that can complete the process of tumor destruction and prevent disease recurrence. Our lead platforms, derived from either vesicular stomatitis virus (VSV) or measles virus, are being evaluated in ongoing Phase 1-2 clinical trials addressing multiple cancer types.

Vyriad and Regeneron (NASDAQ: REGN) are engaged in a broad strategic agreement for the discovery and development of new oncolytic virus treatments for cancer leveraging Vyriad's VSV platform and Regeneron's PD-1 inhibitor Libtayo(r) (cemiplimab) as well as its unmatched antibody discovery capabilities. Vyriad is a privately held company based in Rochester, Minnesota.

For more information, visit hhttps://vyriad.com/.

CONTACTS:

Investor Relations:

Barb Duckett

bduckett@vyriad.com

(507) 289-0944

Media Relations:

mediarelations@vyriad.com

Related link: https://vyriad.com/

This news story was published by the Neotrope® News Network - all rights reserved.

Business, Free News Articles, Software

Blockit Announces No Cost Third Dose Online Scheduling Functionality For COVID-19 Vaccinations

MCKINNEY, Texas -- Blockit Now Inc., a leading provider of digital care coordination solutions, announced today that it will expand the license use of the no cost version of its award-winning, HIPAA compliant, online vaccination scheduling solution to include third dose of the Pfizer and Moderna COVID-19 vaccines to eligible immunocompromised patients. The offering is intended to ease the monumental effort by providing an easy-to-use online schedule system that has already been used in complex healthcare scheduling use cases to schedule nearly 1.5 million vaccinations.

This represents a significant effort to help continue to increase the efficiency of COVID-19 vaccination coordination and minimize the stress on both providers and patients during this difficult time. Since the launch of the COVID-19 scheduling offering, Blockit has worked continuously to increase relevant features and support the needs of healthcare workers, patients, government officials, clients and other organizations focused on helping Americans through this Pandemic.

"This offering along with Blockit's efforts delivering an amazing solution for monoclonal antibody treatment scheduling continues to prove our commitment to make healthcare happen through innovative enabling technologies across the continuum of care," said Blockit's CEO, Jake McCarley.

Since initially announcing Blockit's free COVID-19 test scheduling offering in March of 2020, Blockit has continued to offer additional no cost functionality enabling both large and small organizations to improve their administration and patient experience.

"Our goal has always been to use innovative technology to simplify patient access while improving patient outcomes and reducing excess work for healthcare professionals," said Blockit SVP CCO, Dave Gregorio. "With the continued spread of COVID-19 and the additional vaccination effort, we are honored to support the front line delivery organizations with no cost access to our leading digital care coordination solutions."

For healthcare organizations interested in utilizing this service to easily publish and seamlessly manage COVID-19 vaccination scheduling, please visit https://www.blockitnow.com/covid and follow the quick and simple five minute enrollment.

About Blockit:

Blockit's focus on simplifying healthcare processes for everyone has led to being the leading platform that improves patient access that leads to better patient outcomes. By combining advanced technology with expert service and support, Blockit removes the barriers that stand in the way of patient access, seamless closed loop referrals and optimal care coordination.

Learn more: https://www.blockitnow.com/

MEDIA ONLY CONTACT:
Dave Gregorio
SVP, Chief Customer Officer
dave.gregorio@blockitnow.com
‪(248) 215-2729‬

Related link: https://www.blockitnow.com/

This news story was published by the Neotrope® News Network - all rights reserved.

Free News Articles

Modern Foot & Ankle Welcomes New Podiatrist to Casselberry Clinic

CASSELBERRY, Fla. -- There's a new face in town for your feet. Jacob Huffman, D.P.M., joined the podiatric group Modern Foot & Ankle in July. Last week, he became the sole practitioner of the Casselberry clinic.

"This has been a great opportunity for me," said Dr. Huffman. "Modern Foot & Ankle is a group of physicians with a common mindset and goal: to provide high-quality patient care and utilize all available resources to ensure the patient has the best outcome."

After earning his medical degree from Barry University in Miami and completing his surgical residency at the Miami VA Medical Center, Dr. Huffman, who was born and raised in Central Florida, was excited to return to the Orlando area.

"As a young man growing up in the small suburb of Apopka, I feel I was shaped by Orlando- with the magic of Disney in my backyard and the natural wonders of Wekiwa State park just down the street," he said. "This combination helped shape my wonder and amazement for science and education."

Dr. Huffman said he's proud to serve the growing city and give back to his neighbors as a physician. He added that he's excited to offer patients the groundbreaking services he received advanced training on during his surgical program.

"Having the opportunity to work in the VA and UM health system exposed me to some of the newest up-and-coming technologies that have provided me with the mindset of constant evolution in pursuit of quality patient care," said Dr. Huffman.

His specialties, which include minimally-invasive bunion and hammertoe corrections, fall in line with the group's focus on continually discovering new technologies and techniques.

"I believe Modern Foot & Ankle provides something that most cannot," he said. "We offer technologically-based patient care while still providing patients with the small-town warmth of your local practice."

As a physician, Dr. Huffman said he enjoys "explaining the etiology and using a systematic approach to help tailor each treatment plan to the patient's needs." He feels that having the patient engaged in their treatment not only ensures that they fully understand the condition but aids them once they are out of the office.

Moreover, helping patients find immediate relief for the variety of conditions seen in podiatry garners him great personal and professional satisfaction.

"From removing a foreign object or an ingrown toenail to alleviating heel pain with an injection, seeing the smile on patients' faces makes everything worth it," he said.

The clinic is located at 178 Wilshire Blvd., in Casselberry. The location's former provider, Dr. Roma Patel, recently moved to the group's newest office in Winter Garden, Fla., which celebrated its grand opening last g Monday.

About Modern Foot & Ankle®

Through Big-City Technology. Small-Town Care.® Modern Foot & Ankle has reshaped the patient experience and curated a progressive model for podiatric healthcare. The board-certified physicians provide comprehensive medical and surgical solutions for foot and ankle conditions in clinics across Central Florida. With 24/7 online booking and check-in, extended office hours, advanced on-site equipment, and cutting-edge treatment options, Modern Foot & Ankle serves patients efficiently, comfortably, and on their schedule. For more information, visit http://www.modernfootankle.com/.

Contact: Lindsay Siegel, Modern Foot & Ankle
Phone: (813) 549-5678
Email: marketing@mfahealth.com

Related link: http://modernfootandankle.com/

This news story was published by the Neotrope® News Network - all rights reserved.

Alliances and Partnerships, Business, Education and Schools, Free News Articles

AMI Expeditionary Healthcare and Maclean Health announce partnership to provide COVID-testing, vaccinations, and other safety measures to help California schools to open safely

SACRAMENTO, Calif. -- AMI Expeditionary Healthcare, an international health-care provider with unparalleled experience in responding to global pandemics, and Maclean Health, a renowned Disabled Veteran Business Enterprise (DVBE) healthcare distributor, have teamed up to deliver COVID testing, vaccinations, and healthcare supplies to school districts with the support of California School Boards Association (CSBA).

CSBA brings together school governing boards, and administrators from districts and county offices of education to advocate for effective policies that advance the education and wellbeing of the state's more than 6 million school-age children.

"This approach will ensure cost-effective vaccinations and individual COVID testing and early detection of positive cases enabling California schools to open its doors knowing that its teachers, staff, and students are healthy," said Mike Smith, Executive Vice President, Operations, AMI Expeditionary Healthcare.

AMI has been providing COVID-19 testing services since May 2021 to schools and static sites in the South, West, and Central districts for the Los Angeles Unified School District (LAUSD). AMI currently has 800 employees across 18 locations conducting 250,000 tests per week for on-campus students and staff as wells as homebound special needs individuals.

"We are proud during this ongoing pandemic to be able to help the state of California open its school doors knowing that its students, educators, and staff have the best chance of remaining COVID-free with a robust testing and vaccination solution," said Tony Campos, COO of Maclean Health. "This partnership enables us to apply all preventive measures to make sure that California's students, teachers, school administrators and faculty, as well as communities at large, are safe."

At the end of 2020, Maclean Health was awarded the State of California Face Mask Contract, which is a mandatory contract for all California state agencies. To date, Maclean has delivered large volumes of these critical masks to many California departments and agencies, including the Department of Education, Department of Social Services, Department of General Services, Department of Veterans Affairs, Correctional Health Care Services, CalFire, Department of Health Care Services, and various unified school districts.

This unique partnership will be guided by the experience of AMI's Global Health Director Dr. Thomas Crabtree who brings his experience in helping to eradicate Ebola and Dr. Scott Giberson, a retired Rear Admiral and experienced public health leader.

For more information about AMI Expeditionary Healthcare, please visit https://ami.health/.

For more information about Maclean Health, please visit https://www.macleanhealth.com/.

For any questions, please contact info@macleanhealth.com

Related link: https://ami.health/

This news story was published by the Neotrope® News Network - all rights reserved.